Prognostix

PrognostiX, a privately-held spin out of the Cleveland Clinic Foundation, is focused on cardiovascular disease management. The company's CardioMPO™ test, which aids in the diagnosis of near-term heart attack and cardiac death risk is the first FDA-cleared diagnostic of its kind. PrognostiX's proprietary product pipeline includes valuable, high-margin cardiovascular and inflammatory biomarkers licensed to it exclusively by the Cleveland Clinic, the world's most respected cardiovascular center. The company operates a CLIA-certified and CAP-accredited specialty reference laboratory, enabling it to bring promising new cardiovascular biomarkers to market